BCR and cancer: It is also consistent with Nguyen et al.'s meta-analysis that also found that treatment delays up to 3 months are safe for all localized PCas, and even delays beyond 6–9 months were inconsistently associated with adverse outcomes—limited to increased risk of BCR and worse pathology, but not impacting cancer-specific or overall survival [14].